Search results
7 wrz 2021 · Dexamethasone for moderate-severe COVID-19 infections was the most cost-effective strategy and would have minimal budget impact. Based on current data, remdesivir is unlikely to be a...
21 lut 2023 · We conducted a systematic review and individual patient data meta-analysis to evaluate the benefits and harms of remdesivir compared with placebo or usual care in patients treated in hospital for COVID-19 and whether treatment effects differed between subgroups of patients.
22 kwi 2022 · This press release was updated on 4 May 2022 to provide more details on the conditional recommendation for the use of remdesivir in certain patients.Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the be...
19 lut 2022 · This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing and reimbursement efforts.
19 mar 2022 · Priced at $520 per vial ($3120 for the 5-day treatment course) in the United States and £340 per vial (£2040 for the 5-day treatment course) in the United Kingdom, remdesivir has been at the center of a debate regarding how to assess its value for treating COVID-19.
12 paź 2022 · Cost estimates for remdesivir ranged widely, from $10 to $780 for a 10-day course. In three out of four included economic evaluations, remdesivir treatment scenarios were cost-effective, ranging from ~ 8 to ~ 23% of the willingness-to-pay threshold for the respective country.
Results: At a unit price of $520 per vial and assuming no survival benefit with remdesivir, the incremental cost-effectiveness was $298 200/QALY for patients with moderate to severe COVID-19 and $1 847 000/QALY for patients with mild COVID-19.
